Cancer Institute and Hospital, Chinese Academy of Medical Sciences
The mechanism of action of cidabenamide and the advantages of vincristine metronomic chemotherapy make it possible to combine the two drugs. Therefore, it is necessary to conduct a prospective study to investigate the value of chidamide in combination with vincristine metronomic treatment for triple-negative breast cancer.The current study was designed to explore the efficacy of oral two-metronomic agents (chidamide in combination with vincristine) in advanced triple-negative patient in China.
Age
18–75
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
female;
aged ≥ 18 years and ≤75 years;
histologically proved metastatic triple-negative breast cancer;
at least one measurable or evaluable lesion based on RECIST 1.1 criteria;
estimated life expectancy ≥ 3 months; (6) normal heart, liver, and kidney function;
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1; -
informed consent signed by the participants.
You may not be if
received neoadjuvant or adjuvant therapy containing vinorelbine or capecitabine within one year prior to treatment initiation;
participated in other new drug clinical trials within 4 weeks before enrollment;
inflammatory breast cancer;
symptomatic visceral disease;
second primary malignancy;
mental disorder.
Clareo Health | Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer
